Status:
COMPLETED
Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Rheumatoid Arthritis
Spondyloarthritis
Eligibility:
All Genders
18+ years
Brief Summary
TNFα inhibitors have revolutionized the management of patients suffering from inflammatory diseases in the field of rheumatology. Infliximab remains widely used in France, and infliximab biosimilars h...
Detailed Description
TNFα inhibitors have revolutionized the management of patients suffering from inflammatory diseases in the field of rheumatology. Infliximab remains widely used in France, and infliximab biosimilars h...
Eligibility Criteria
Inclusion
- Patients aged 18 or older
- Patients who has received at least 3 IV infliximab infusions and suffer from chronic inflammatory rheumatic condition
- Absence of disease flare / progressive disease preventing the continuation of infliximab
- Patient affiliated to national insurance
Exclusion
- Any patient whose doctor considers that he will not be able to comply with the obligations of the trial
- Patients under curatorship or tutorship
- Pregnant women
Key Trial Info
Start Date :
February 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 16 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT05424926
Start Date
February 24 2023
End Date
December 16 2024
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rheumatology Department, Cochin Hospital
Paris, IDF, France, 75014